Antiretroviral Therapy–Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial | Zendy

Ighovwerha Ofotokun | Zendy; Lauren F. Collins | Zendy; Kehmia Titanji | Zendy; Antonina Foster | Zendy; Caitlin A. Moran | Zendy; Anandi N. Sheth | Zendy; Cecile D. Lahiri | Zendy; Jeffrey L. Lennox | Zendy; Laura Ward | Zendy; Kirk A. Easley | Zendy; M. Neale Weitzmann | Zendy

Open Access

Antiretroviral Therapy–Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial

Author(s) -

Ighovwerha Ofotokun,

Lauren F. Collins,

Kehmia Titanji,

Antonina Foster,

Caitlin A. Moran,

Anandi N. Sheth,

Cecile D. Lahiri,

Jeffrey L. Lennox,

Laura Ward,

Kirk A. Easley,

M. Neale Weitzmann

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz1027

Subject(s) - medicine , n terminal telopeptide , placebo , zoledronic acid , bone resorption , bone remodeling , bone mineral , osteoporosis , urology , femoral neck , clinical endpoint , gastroenterology , randomized controlled trial , pathology , alkaline phosphatase , biochemistry , chemistry , alternative medicine , osteocalcin , enzyme

Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among persons with HIV (PWH). We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induced bone loss through 48 weeks of therapy and here investigate whether protection persisted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research